There is an interesting article
published in the June issue of Radiology.
The authors have used a STIR TSE sequence in patients with bronchogenic carcinoma to try and distinguish metastatic from non-metastatic nodes. The criteria were both quantitative (using a lymph node-saline signal intensity ratio) and qualitative (based on the brightness of the node).
In small and large nodes, the sequence performed well, showing a sensitivity of 93% and a specificity of 87% on a per-patient basis for picking up mediastinal lymph node metastases. With qualitative analysis, the sensitivity was 88% and the specificity, 86%.
These results are much better than those obtained with just using the size criterion with CT or MRI. The results are also almost as good as those obtained with FDG-PET, which is where the article really starts becoming interesting.
Practically, if these results can be reproduced at other centres, MRI could become a one-stop shop for staging bronchogenic carcinoma. Instead of using CT, PET-CT or PET in various combinations, one could just do a contrast-enhanced MRI and get all the answers. A whole body STIR can also be thrown in to look for occult metastases elsewhere.